As of November 6, 2026, Nautilus Biotechnology, Inc. is a publicly traded company (Nasdaq: NAUT). The largest holder reporting an active stake on Schedule 13D is Parag Mallick, the chief scientist and a director, at 17.6%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Sujal M. Patel, the chief executive and president (16.3%) (Schedule 13D/A, March 4, 2026).
Is this your company?
About to sign with, pay or invest in Nautilus Biotechnology, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Nautilus Biotechnology, Inc. a real, registered company?
- Nautilus Biotechnology, Inc. files with the SEC under CIK 1808805 (its SEC filings).
- Its shares are listed under the ticker NAUT on Nasdaq (SEC company record).
- business address in Seattle, Washington, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Nautilus Biotechnology, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names AH Bio Fund II, L.P. (filed 2026-08-28).
Who are Nautilus Biotechnology, Inc.'s owners and officers?
Nautilus Biotechnology, Inc.: business address in Seattle, Washington; industry Laboratory Analytical Instruments (Schedule 13D/A, 2026-11-03).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-11-03 | Perceptive Advisors LLC | 3.9% |
| Schedule 13D/A, 2026-09-11 | Ah Bio Fund Ii, L.P. | 4.9% |
| Schedule 13D/A, 2026-08-28 | Ah Bio Fund Ii, L.P. | 6% |
| Schedule 13D/A, 2026-08-14 | Perceptive Advisors LLC | 9.1% |
| Schedule 13D/A, 2026-06-30 | Ah Bio Fund Ii, L.P. | 7.1% |
| Schedule 13D/A, 2026-06-04 | Ah Bio Fund Ii, L.P. | 9.9% |
| Schedule 13D/A, 2026-03-04 | Parag Mallick | 17.6% |
| Schedule 13D/A, 2026-03-04 | Sujal Patel | 16.3% |
Questions about who owns Nautilus Biotechnology, Inc.
Who owns Nautilus Biotechnology, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Nautilus Biotechnology, Inc.: Parag Mallick (17.6%, Schedule 13D/A, filed 2026-03-04) and Sujal Patel (16.3%, Schedule 13D/A, filed 2026-03-04).
Who are the largest shareholders of Nautilus Biotechnology, Inc.?
By the share each holder's latest filing reports, the largest holders of Nautilus Biotechnology, Inc. on this page are Parag Mallick (17.6%) and Sujal Patel (16.3%).
When did Parag Mallick buy into Nautilus Biotechnology, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Parag Mallick on this page is the Schedule 13D/A, filed 2026-03-04, reporting 17.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Nautilus Biotechnology, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Nautilus Biotechnology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nautilus Biotechnology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Nautilus Biotechnology, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief scientist and a director: 20,493,392 shares (16.1% of shares outstanding) (Form 4, 2025-05-12).
- , the chief executive and president: 17,461,232 shares (13.7% of shares outstanding), 10,366,721 held directly and 7,094,511 indirectly (Form 4, 2026-03-04).
- , a 10% owner: 12,653,917 shares (9.9% of shares outstanding), held indirectly through By AH Bio Fund II, L.P. and 1 other, on a joint filing (Form 4, 2026-06-04).
- AH Bio Fund II, L.P., a 10% owner: 12,653,917 shares (9.9% of shares outstanding), held indirectly through By AH Bio Fund II, L.P. and 1 other, on a joint filing (Form 4, 2026-06-04).
- AH Equity Partners LSV II, L.L.C., a 10% owner: 12,653,917 shares (9.9% of shares outstanding), held indirectly through By AH Bio Fund II, L.P. and 1 other, on a joint filing (Form 4, 2026-06-04).
Shares outstanding: 127,372,425 as of 2026-10-22, from the company's latest SEC cover page.
How much has Nautilus Biotechnology, Inc. raised?
No fundraising or offering filing from Nautilus Biotechnology, Inc. is on file with us.
Keep reading
More on Nautilus Biotechnology, Inc. and the records around it.
Nautilus Biotechnology, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026), Kardigan, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/nautilus-biotechnology